$TECH QuantLogix Newsdesk · June 26, 2026 at 4:31 PM UTC

Merck KGaA Offers $73 Per Share Cash Bid for Bio-Techne (TECH)

What happened

German pharmaceutical and life-science group Merck KGaA announced a cash acquisition offer for Bio-Techne at $73 per share. The all-cash structure removes financing contingency risk typical of larger deal structures. Bio-Techne, a Minneapolis-based developer of proteins, antibodies, and immunoassay tools for research and diagnostics, has a market footprint spanning both biopharma and clinical lab end-markets. The $73 offer sits above TECH's reference price of $71.02 cited in the signal context.

The QL Read

TECH's composite signal sits at 64/100 (bullish bias) with shares at $71.02 — a roughly 2.8% spread to the $73 offer price, consistent with standard deal-risk arbitrage. Broad market breadth of 64.8% advancing provides a constructive tape backdrop as the deal progresses.

Source: The Motley Fool — "Stock Market Today, June 25: Bio-Techne Surges After Merck KGaA Announces $73-Per-Share Cash Acquisition Offer" — 2026-06-25T21:23:42Z

Not financial advice. QuantLogix is a research platform; nothing in this brief constitutes a recommendation to buy or sell any security. We summarize public news with attribution to the original publisher; visit the source above for the full original article.